甲羟孕酮与炔诺酮治疗功能失调性子宫出血的效果比较

Medroxyprogesterone versus norethindrone in treatment of dysfunctional uterine bleeding

目的比较甲羟孕酮与炔诺酮治疗功能失调性子宫出血的效果。方法选取本院2013年5月至2014年9月收治的112例功能失调性子宫出血患者为研究对象，将其随机分为A组和B组，每组56例。A组采用甲羟孕酮治疗，B组采用炔诺酮治疗。比较两组治疗后月经周期、经期天数、血红蛋白水平、子宫膜厚度和不良反应发生率。结果A组月经周期、经期天数与B组比较，差异无统计学意义（P〉0．05）；A组Hb水平为（107．25±21．19）g/L，显著高于B组的（96．54±30．07）g／L（P〈0．05）；A组子宫膜厚度为（5．75±1．26）mm，显著小于B组的（7．43±1．85）mm（P〈0．05）。A组不良反应发生率为3．6％，显著低于B组的14．3％（P〈0．05）。结论与炔诺酮相比，甲羟孕酮治疗功能失调性子宫出血可以更有效地控制阴道出血，改善血红蛋白水平和子宫内膜厚度，疗效显著，安全可靠，值得临床应用和推广。

Objective To explore the effect of medroxyprogesterone versus norethindrone in the treatment of dysfunctional uterine bleeding. Methods 112 patients with dysfunctional uterine bleeding treated at our hospital from May, 2013 to September, 2014 were selected as study objects and were randomly divided into group A and group B, 56 cases for each group. Group A were treated with medroxyprogesterone and group B norethindrone. After the treatment, the menstrual cycle, period days, hemoglobin level, uterine veil thickness, and incidence of adverse reactions were compared between these two groups. Results There were no statistical differences in menstrual cycle and period days between these two groups （P〉0.05）. The Hb level was （107.25±21.19）g/L in group A and （96.54±30.07）g/L in group B （P〈0.05）. The uterine veil thickness was （5.75±1.26） mm in group A and （7.43±1.85） mm in group B （P〈0.05）. The incidence of adverse reactions was 3.6% in group A and 14.3% in group B （P〈0.05）. Conclusion Compared with norethindrone, medroxyprogesterone in the treatment of dysfunctional uterine bleeding is much more effective, safer, and more reliable and can better improve the patients＇ Hb level and uterine veil thickness, so it is worth being clinically generalized.